Miguel Borregón, María Valero, Asia Ferrández, Álvaro Muñoz, Carmen Roque, Javier-David Benítez-Fuentes
{"title":"Cancer-associated thoracic aorta arterial thrombosis: case report and review of the literature.","authors":"Miguel Borregón, María Valero, Asia Ferrández, Álvaro Muñoz, Carmen Roque, Javier-David Benítez-Fuentes","doi":"10.3389/fcvm.2025.1480310","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge.</p><p><strong>Key clinical question: </strong>Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed.</p><p><strong>Clinical approach: </strong>We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy.</p><p><strong>Conclusions: </strong>This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1480310"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1480310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge.
Key clinical question: Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed.
Clinical approach: We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy.
Conclusions: This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.